The DPP9 Knockout HEK293T Polyclonal Cells product provides a heterogeneous CRISPR/Cas9-edited cell population with targeted disruption of the DPP9 gene. As a polyclonal knockout pool, it retains biological variability while ensuring robust functional ablation of DPP9, making it suitable for loss-of-function studies without the constraining effects of clonal selection. This model enables dissection of DPP9??s regulatory roles in inflammasome activation, antigen presentation, and cellular proliferation.
The parental HEK293T cell line originates from human embryonic kidney epithelium, immortalized by adenovirus type 5 DNA and stably expressing SV40 large T antigen. Known for exceptional transfectability and episomal plasmid replication, these cells are a mainstay for protein expression and pathway reconstitution. Their epithelial origin provides a relevant context for studying DPP9-mediated processes.
DPP9 encodes a serine protease that cleaves N-terminal dipeptides from substrates including NLRP1 and antigenic peptides, serving as a crucial suppressor of the NLRP1 inflammasome. DPP9 constitutively binds NLRP1 and DPP8 to prevent spontaneous oligomerization. Inflammatory cytokines like TNF-?? and IL-1?? upregulate DPP9 via NF-??B, while loss of DPP9 triggers NLRP1-dependent ASC speck assembly, caspase-1 activation, and secretion of mature IL-1?? and IL-18. DPP9 also trims precursors loaded onto MHC class I through TAP1/TAP2, influencing CD8+ T cell responses. Beyond immunity, DPP9 interacts with Filamin A to modulate adhesion and migration, and controls mTORC1 signaling to regulate proliferation and apoptosis.
HEK293T cells lack endogenous NLRP1 but express downstream inflammasome components, making DPP9 knockout an ideal platform for reconstitution experiments. The polyclonal pool minimizes clonal bias and permits robust analysis of pyroptosis, cytokine release, and MHC-I surface expression. Co-immunoprecipitation assays with NLRP1, DPP8, and Filamin A, alongside pharmacological inhibition, are readily performed. This model also supports mTORC1 pathway interrogations relevant to cancer cell growth.
Key applications include inflammasome activation measured by LDH release and IL-1?? ELISA, antigen presentation quantitated via MHC-I flow cytometry, and DPP9 inhibitor screening using enzymatic activity assays. Additionally, these cells facilitate studies of fibrosis and autoimmune disease mechanisms. For more information, contact Ascent Research.
